The emerging class of GLP-1 receptor agonist and GIP co-agonist medications, including tirzepatide, semaglutide, and the newly introduced retatrutide, provide groundbreaking advances in the control. https://tirzepatide413897.gynoblog.com/42338688/tirzepatide-a-thorough-review